Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease
- 9 July 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 93 (2), e135-e142
- https://doi.org/10.1212/wnl.0000000000007694
Abstract
Objective To verify the previously reported association between long-term use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson disease (PD), respectively. Methods We obtained odds ratios (ORs) associating time of β2AR agonist and antagonist use with PD risk in nationwide Danish health registries. Results We included 2,790 patients with PD and 11,160 controls. Long-term β2AR agonist use was associated with reduced PD risk (OR 0.57, 95% confidence interval [CI] 0.40–0.82) in this cohort. Unexpectedly, short-term β2AR agonist use was equally associated (OR 0.64, 95% CI 0.42–0.98). Because β2AR agonists are prescribed mostly for chronic obstructive pulmonary disease (COPD), often caused by long-term nicotine abuse, we analyzed other markers of smoking. Diagnosis of COPD (OR 0.51, 95% CI 0.37–0.69) and use of inhaled corticosteroids (OR 0.78, 95% CI 0.59–1.02) or inhaled anticholinergics (OR 0.41, 95% CI 0.25–0.67) were also inversely associated with PD. Increased PD risk was not found for all β2AR antagonists but only for propranolol and metoprolol. Associations were markedly stronger for short-term than long-term use. Conclusion We confirmed β2AR agonist use to be associated with reduced PD risk and β2AR antagonist use with increased PD risk. However, our data indicate the association of β2AR agonists to be indirectly mediated by smoking, which is repeatedly associated with reduced risk of PD. The association of β2AR antagonists indicates reverse causation, with PD symptoms triggering their prescription rather than β2AR antagonists causing PD. Thus, current epidemiologic data do not support a causal link between β2AR agonists and antagonists and PD risk.Keywords
This publication has 18 references indexed in Scilit:
- β2-Adrenoceptor Agonists and Antagonists and Risk of Parkinson's DiseaseMovement Disorders, 2018
- β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s diseaseScience, 2017
- Refining estimates of prescription durations by using observed covariates in pharmacoepidemiological databases: an application of the reverse waiting time distributionPharmacoepidemiology and Drug Safety, 2017
- Data Resource Profile: The Danish National Prescription RegistryInternational Journal of Epidemiology, 2016
- Determining prescription durations based on the parametric waiting time distributionPharmacoepidemiology and Drug Safety, 2016
- The Danish National Patient Registry: a review of content, data quality, and research potentialClinical Epidemiology, 2015
- Database on Danish population-based registers for public health and welfare research.Scandinavian Journal of Public Health, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987